KMT2A and acute myeloid leukemia: As a result, pan-BETi compounds have been demonstrated to be potent anti-tumor agents in the context of NUT midline carcinoma22, acute myeloid leukemia, mixed lineage leukemia24, MLL-fusion leukemia50, multiple myeloma51, lung adenocarcinoma25, glioblastoma52, and neuroblastoma53.